1Q Revenues: $5.6 billion (-4%)
1Q Earnings: $1.0 billion (-4%)
Comments: Decline in revenues was driven by Zyprexa patent expirations, partially offset by Cymbalta, Forteo, Humalog, and Effient product growth, as well as a 41% revenue growth in China. Cymbalta sales were $1.1 billion, up 23%. Effient sales were $115.8 million, up 106%. Forteo sales were $271.3 million, up 26%. Humalog sales increased 12% to $590.3 million. Animal health products were $490.7 million, up 33%.